XXII stock forecast, quote, news & analysis

Key Takeaways

• 22nd Century Group shares fell roughly 92% over the past 30 days, sliding from about $0.91 to about $0.07.
• The decline was amplified by aggressive equity issuance: an at-the-market offering expanded the share count more than fivefold in a single day in late October.
• Preliminary third-quarter results showed 66% sequential revenue growth and a return to positive gross profit, but the company remained deeply unprofitable with limited cash.
• The quarterly move was even steeper, down roughly 98%, extending a multi-year pattern of reverse stock splits and repeated dilution.
• Nasdaq minimum-bid compliance and the funding runway are now central risks for investors to monitor.
• For additional detail, explore XXII Price Targets, Earnings, and Forecast pages.
• Readers interested in automated strategies can also explore Trending AI Robots.

22nd Century Group (XXII) Company Overview and Market Position

22nd Century Group, Inc. is a tobacco products and plant-biotechnology company headquartered in Mocksville, North Carolina. The company is best known for VLN, a proprietary cigarette engineered to contain roughly 95% less nicotine than conventional cigarettes, and it markets reduced-nicotine products under the VLN and Pinnacle brands. The business also generates revenue through contract manufacturing, producing cigarettes and filtered cigars for third-party brands.

Investors follow XXII because of its distinctive regulatory positioning: the U.S. Food and Drug Administration has authorized reduced-nicotine claims for its combustible products, positioning the company as an early mover in a potential low-nicotine tobacco category. That opportunity, however, is offset by a small revenue base, recurring operating losses, and a long history of reliance on dilutive equity financing, which has kept the stock in distressed micro-cap territory.

22nd Century Group (XXII) Stock Price Performance: Last 30 Days vs. Quarter

Over the past 30 days, XXII declined roughly 92%. The shares closed near $0.91 in early October and fell to about $0.07 by early November, a move of approximately -91.9%. The decline was not gradual: several sessions produced single-day drops of more than 20%, including a decline of more than 46% in mid-October and a drop of more than 55% in a single session in late October.

The quarterly trend was even more severe. From roughly $4.41 in early August to about $0.07 in early November, the stock lost approximately 98% of its value. This extended a longer multi-year downtrend, with the shares down well over 99% on a split-adjusted basis over the trailing year, reflecting repeated reverse splits and continuous share issuance rather than a single isolated event.

What Drove XXII Stock Price in the Last 30 Days

The dominant catalyst was dilution. In late October, 22nd Century Group expanded its at-the-market (ATM) offering program and issued shares into the open market at a rapid pace. According to the company's prospectus supplement, shares outstanding rose from roughly 3.4 million on October 22 to more than 19.2 million the following day, an increase of more than fivefold in a single day, as the company sold approximately 15.8 million shares for roughly $4.7 million in gross proceeds. The program was subsequently expanded to allow up to an additional $18.8 million in sales.

Operational results, announced around the same time, told a mixed story. Preliminary unaudited third-quarter results reported net revenue up 66% sequentially to about $4.8 million, gross profit turning positive at roughly $0.4 million, and a narrowed net loss of about $2.6 million. Despite the improvement, the company remained unprofitable, and gross margin was roughly 8% on a small revenue base, leaving cash and equivalents near $3.9 million at quarter-end. The market focused on the capital-structure risk, and the shares fell sharply even as the revenue figures improved.

What Drove XXII Stock Performance Over the Last Quarter

The quarterly decline reflects a longer-running, self-reinforcing cycle. 22nd Century Group has repeatedly used reverse stock splits and equity sales to maintain its Nasdaq listing and fund operations, including a 1-for-20 reverse split in June 2026 and a 1-for-15 split earlier in 2026. Each round of issuance expands the share count and dilutes existing holders, while the reverse splits raise the nominal share price without adding underlying value.

Against that backdrop, investor concerns about the minimum bid price requirement, thin cash reserves, and the company's ability to fund its VLN expansion strategy have kept selling pressure elevated. The fundamental progress in distribution and revenue has so far been outweighed by the persistent overhang of financing-related risk.

Trending AI Robots

Tickeron's Trending AI Robots page offers a curated view of AI-driven trading bots across thousands of tickers. Tickeron operates hundreds of automated strategies, but only the top-performing and most relevant bots are featured in this section, helping traders filter a broad universe down to a focused selection. The bots vary widely in strategy, timeframe, and performance metrics, so the page is designed for users who want to compare approaches rather than follow a single signal. For those interested in systematic trading tools, the Trending AI Robots section provides a practical starting point for exploring data-driven automation.

XXII Stock Forecast Drivers: What Investors Should Watch Next

Investors monitoring XXII should focus on several forward-looking factors. First, the company's upcoming third-quarter earnings report and any updated full-year guidance will be key tests of whether recent revenue momentum can be sustained. Second, any further ATM sales or new financing announcements will directly affect the share count and dilution outlook. Third, Nasdaq listing compliance, particularly the minimum bid price requirement, remains a live risk that could trigger additional reverse splits or delisting proceedings. Finally, the pace of VLN and Pinnacle distribution expansion, retailer adoption, and any regulatory developments around reduced-nicotine tobacco standards will shape the longer-term demand story. Each of these factors carries meaningful uncertainty, and none should be read as a recommendation to buy or sell the stock.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations